Inhibitory effect of salvinorin A, fromSalvia divinorum, on ileitis‐induced hypermotility: cross‐talk between κ‐opioid and cannabinoid CB1receptors
Open Access
- 1 November 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (5) , 681-689
- https://doi.org/10.1038/bjp.2008.294
Abstract
Background and purpose: Salvinorin A, the active component of the hallucinogenic herbSalvia divinorum, inhibits intestinal motility through activation of κ‐opioid receptors (KORs). However, this compound may have target(s) other than the KORs in the inflamed gut. Because intestinal inflammation upregulates cannabinoid receptors and endogenous cannabinoids, in the present study we investigated the possible involvement of the endogenous cannabinoid system in salvinorin A‐induced delay in motility in the inflamed gut.Experimental approach: Motilityin vivowas measured by evaluating the distribution of a fluorescent marker along the small intestine; intestinal inflammation was induced by the irritant croton oil; direct or indirect activity at cannabinoid receptors was evaluated by means of binding, enzymic and cellular uptake assays.Key results: Salvinorin A as well as the KOR agonist U‐50488 reduced motility in croton oil treated mice. The inhibitory effect of both salvinorin A and U‐50488 was counteracted by the KOR antagonist nor‐binaltorphimine and by the cannabinoid CB1receptor antagonist rimonabant. Rimonabant, however, did not counteract the inhibitory effect of salvinorin A on motility in control mice. Binding experiments showed very weak affinity of salvinorin A for cannabinoid CB1and CB2and no inhibitory effect on 2‐arachidonoylglycerol and anandamide hydrolysis and cellular uptake.Conclusions and implications: The inhibitory effect of salvinorin A on motility reveals a functional interaction between cannabinoid CB1receptors and KORs in the inflamed—but not in the normal—gutin vivo.British Journal of Pharmacology(2008)155, 681–689; doi:10.1038/bjp.2008.294; published online 14 July 2008Keywords
This publication has 59 references indexed in Scilit:
- Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated ratsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Cannabidiol, extracted fromCannabis sativa, selectively inhibits inflammatory hypermotility in miceBritish Journal of Pharmacology, 2008
- Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammationBritish Journal of Pharmacology, 2008
- Endocannabinoids and the gastrointestinal tract: what are the key questions?British Journal of Pharmacology, 2007
- Guide to Receptors and Channels, 2nd edition (2007 Revision)British Journal of Pharmacology, 2007
- Endocannabinoid overactivity and intestinal inflammationGut, 2006
- Investigation on the relationship between cannabinoid CB1and opioid receptors in gastrointestinal motility in miceBritish Journal of Pharmacology, 2006
- Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipationBritish Journal of Pharmacology, 2006
- Screening the receptorome for plant-based psychoactive compoundsLife Sciences, 2005
- Loperamide effects on hepatobiliary function, intestinal transit and analgesia in miceLife Sciences, 1994